Materials and Methods Experimental Research Methods The study included 225 obese patients
Originally developed and FDA-approved for managing type 2 diabetes, Ozempic belongs to a group of medications known as GLP-1 receptor agonists
This exceeded outcomes reported for semaglutide (~15%) and tirzepatide (~22%) in comparable timeframes, representing the largest effect size for any metabolic peptide in published Phase II data at that time
In contrast, antagonism of H 3 receptors, which are predominantly expressed in the CNS and act as autoreceptors in presynaptic neurons, ability to control histamine turnover has resulted in weight loss or to prevent weight gain
Remember that these medications are not a substitute for a balanced diet and regular exercise, but are used alongside these lifestyle modifications
4 TABLE 1 lists the FDA-approved indications for the various brands of GLP-1 and dual GIP/GLP-1 RAs